Cells that lack PARP-1 activity are limited in their ability to repair DNA single strand breaks and respond to DNA damage with a strong accumulation of p53 and enhanced rates of apoptotic cell death. We have generated combinatorial mutant mice that both lack p53 and PARP-1 activity due to the expression of a dominant negative PARP-1 allele targeted to T-cells by the lck promoter. Here we report that these double mutant mice develop T-cell lymphoma at a signi®cantly reduced latency period compared to single p53 null mice that are already cancer prone. We demonstrate that the absence of p53 does not only protect T-cells from lck-PARP-DBD transgenic mice from apoptosis but also abrogates the DNA damage induced cell cycle arrest in the G1 phase. T-cells from double mutant mice continue to proliferate after the induction of DNA strand breaks, are limited in their DNA repair capacity and cannot be eliminated by apoptosis. These results indicate that PARP-1 and p53 cooperate in the suppression of tumorigenesis by maintaining genomic integrity after DNA damage through the activation of a G1/S cell cycle checkpoint the initiation of DNA repair and the induction of cell death. Oncogene (2001) 20, 8136 ± 8141.
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Keywords: PARP-1; apoptosis; DNA repair; p53; Tcell lymphoma Poly(ADP-ribose) polymerase (PARP-1) is a sensing molecule with the ability to recognize and bind to regions of damaged DNA in particular to single DNA strand breaks (for review see: de Murcia and MeÂ nissier de Murcia, 1994; Jackson, 1996; Jeggo, 1998) . When cells are exposed to DNA damaging agents and DNA strand breaks are generated, the PARP-1 molecule binds to the damaged site and catalyzes the transfer of ADP-ribose residues from NAD+ to itself and dierent chromatin constituents (Lindahl et al.,, 1995 , Panzeter et al., 1993 . The PARP-1 molecule itself becomes negatively charged by this modi®cation and dissociates from the DNA facilitating DNA repair (Althaus et al., 1994) . PARP-1 de®cient cells are ineective in resealing DNA strand breaks induced by low dose radiation or by various DNA damaging substances and react towards DNA damage with the accumulation of p53 and accelerated apoptosis (Trucco et al., 1998; Beneke et al., 2000; Dantzer et al., 2000) .
These eects of PARP-1 have been reported using cells from PARP-1 null mice generated by gene targeting (de Murcia et al., 1997) but also using thymocytes from transgenic mice which express a dominant negative form of PARP-1 targeted to the T-lymphoid lineage by the proximal lck promoter (lck-PARP DBD, Beneke et al., 2000) . This dominant negative form consists of the DNA binding domain of PARP, i.e. the N-terminus of the PARP-1 protein from aa 1 to 376. We and others have demonstrated before that the expression of this PARP-DBD can eciently block PARP-1 activity in cell lines and in cells from transgenic mice (KuÈ pper et al., 1990 (KuÈ pper et al., , 1995 (KuÈ pper et al., , 1996 Molinete et al., 1993; Schreiber et al., 1995; Beneke et al., 2000) and in particular is eective in inhibiting DNA excision repair (Beneke et al., 2000) . Studies with PARP-1 null mice have revealed that PARP-1 is also instrumental in regulating NF-kB dependent transcriptional regulation (Oliver et al., 1999; Hassa and Hottiger, 1999) . Hence, cells from PARP-1 null mice are defective in both DNA repair and in the transduction of signals that require NF-kB. In contrast, T-cells from lck-PARP-DBD transgenic mice are solely incapable of resealing single strand DNA breaks but maintain other PARP-1 functions.
Since the development of malignant tumors is the consequence of an accumulation of genetic lesions, a lack of DNA single strand repair can be considered a prerequisite for the emergence of malignancies. However, although both PARP-1 de®cient mice and lck PARP-1 DBD transgenics show severe defects in single strand break repair and elevated sister chromatid exchange (Beneke et al., 2000; Conde et al., 2001; Samper et al., 2001 ) the development of spontaneous tumors has never been observed in these mouse mutants (data shown here and Wang et al., 1995; Conde et al., 2001; Tong et al., 2001) . One possible explanation for this is the p53 dependent accelerated rate of apoptotic cell death that is observed in PARP-1 de®cient lymphocytes upon DNA damage. It is likely that this phenomenon leads to the elimination of potentially pre-malignant cells. To explore in more detail a potential role of PARP-1 in tumorigenesis, we set out to investigate whether other genetic events in particular those that block apoptotic cell death could cooperate with the loss of PARP-1 activity in malignant transformation. Therefore, we generated three types of combinatorial mutant mice that are defective in DNA repair due to a block of PARP-1 activity but also lack either the death inducing receptor CD95, the p53 protein or overexpress the antiapoptotic protein Bcl-2. We used the lck-PARP-DBD transgenic mice and crossed them with animals carrying the lpr mutation in the CD95 locus as well as with p53 null mice or with Em bcl-2 transgenic animals which express high levels of Bcl-2 in both B-and T-lymphocytes. The lack of CD95 expression in lpr/lpr mice protects T-cells against cell death following antigenic stimulation, a phenomenon called activation induced cell death (AICD) (for review see Krammer, 2000; Walczak and Krammer, 2000) . In addition, loss or low level CD95 expression has also been reported to counteract DNA damage induced cell death (MuÈ ller et al., 1998) but con¯icting data have also been reported (Newton and Strasser, 2000) . High level expression of the antiapoptotic protein Bcl-2 protects lymphocytes against a wide range of apoptotic stimuli including DNA damage by irradiation (Sentman et al., 1991) . The p53 protein induces apoptosis in response to DNA damage but also activates a damage induced cell cycle checkpoint leading to a G1 arrest (for review see: Lakin and Jackson, 1999; Oren, 1999; Deppert, 1994; Enoch and Norbury, 1995; Levine, 1997) . The lack of p53 predisposes mice for the development of tumors, predominantly thymic T-cell lymphoma (Donehower et al., 1992; Jacks et al., 1994) . We have previously shown that the inability of PARP-1 de®cient T-cells to reseal DNA strand breaks remains unaected in the absence of p53 or by high levels of Bcl-2 (Beneke et al., 2000) .
First we tested the response of thymocytes from these combinatorial mutant mice and wt littermates as a control towards a low dose x-irradiation of 2 Gy that has been shown to predominantly induce DNA single strand breaks. Cell death rates were measured by counting the percentage of cells that contain sub-G1 amounts of propidium iodide-stained DNA after ethanol ®xation as described previously (Darzynkiewicz et al., 1992; Sofer-Levi and Resnitzki, 1996; Beneke et al., 2000) . Comparing thymocytes from lck-PARP-DBD transgenic animals with cells from non transgenic controls we could con®rm our earlier results (Beneke et al., 2000) that showed that PARP-DBD expression correlated with a signi®cantly higher cell death rate upon the induction of DNA damage (Figure 1 ). We found that the deletion of p53 or the coexpression of Bcl-2 is eective in protecting PARP-1 de®cient cells from accelerated cell death, which is also in agreement with our earlier ®ndings (Figure 1 and Beneke et al., 2000) . However the ablation of the death receptor CD95 did not protect PARP-1 de®cient cells from DNA damaged induced cell death suggesting that CD95 is not involved in this pathway (Figure 1) . Regardless of the dierent abilities of Bcl-2 or the lack of CD95 to protect PARP-1 de®cient cells from apoptosis, none of the lck-PARP-1-DBD/lpr,lpr animals nor the lck-PARP-DBD/ Em Bcl-2 animals developed lymphoid malignancies over a period of 12 months (data not shown).
Next, we tested whether the combination of a block of PARP-1 activity and inhibition of apoptosis by Bcl-2 would accelerate tumorigenesis induced by alkylating agents that act through the induction of DNA single strand breaks. To this end, we treated single Em bcl-2 transgenic mice and double lck-PARP-DBD/Em-bcl-2 mutants with a single dose of the carcinogen Nmethylnitrosourea (MNU), which provokes the formation of T-cell lymphoma (Joshi and Frei, 1970; Liu et al., 1994; Karsunky et al., 1999) . After treatment, Tcell lymphomas appeared in thymus, lymph nodes and spleen in both groups of animals as expected but no dierence in the incidence or the latency period was observed between both mutant mouse strains ( Figure  2a ). All tumors were found to be malignant lymphoid neoplasms of B-or T-cell origin judged by the presence of typical surface markers as CD4, CD8, Thy1.2, B220 and of distinct TCR b locus rearrangements in the Figure 1 Death rate of thymocytes from wild-type and several combinatorial mutant mice. Thymocytes were explanted from lck-PARP-DBD transgenic, from non-transgenic controls and from the indicated combinatorial mutant mice and were irradiated (2 Gy) or left untreated. Before treatment and at dierent time points after treatment samples were analysed for the percentage of apoptotic cells. Each data point represents an average value with standard deviation obtained from measurements of three dierent mice. Shown is a representative of three independent experiments. For propidium iodide labeling and the quanti®cation of cell death, cells were washed once with cold PBS and ®xed with ethanol overnight at 7208C. The cells were again washed and then incubated in 2 mg/ml propidium iodide (Sigma) in PBS/ RNase (10 mg/ml) for 30 min at room temperature and analysed by¯ow cytometry. The generation and the characterization of lck-PARP-DBD transgenic mice has been described previously (Beneke et al., 2000) genome of the tumor cells (data not shown). This suggests that pathways solely responsible for the inhibition of apoptosis and the lack of DNA single strand break repair are not complementing each other in the process of tumorigenesis.
In contrast to the co-expression of Bcl-2 or the ablation of CD95, the depletion of p53 in lck-PARP-DBD transgenic mice had a measurable eect on lymphomagenesis. Clearly, lck-PARP-DBD/p53 7/7 mice showed a signi®cantly shortened latency period (97 days) for the development of lymphoid neoplasms than single p53 null mice (168 days) (Figure 2b ). All tumors were manifest in thymus and in peripheral lymphoid organs and with one exception were determined to be of T-cell origin by the presence of T-cell speci®c surface markers (Thy-1, CD4 and CD8) and detectable rearrangement of the TCR b locus (Figure 3 and Table 1 ).
Since p53 is a protein that is not only involved in the induction of apoptosis after DNA damage but also controls and induces cell cycle arrest by activating damage checkpoints we tested whether the presence of the dominant negative PARP-1 allele aected cell cycle progression of T-cells after antigenic stimulation. Splenocytes from wt animals, from lck-PARP-DBD transgenics, from p53 null mice and from combinatorial lck-PARP-DBD/p53 7/7 mice were stimulated with anti CD3 antibodies and the incorporation of 3 Hthymidine was measured before and after a single dose of 2 Gy x-irradiation. Since most of anti CD3 sensitive T-cells in the spleen are in the resting G1/ G0 state, the incorporation of 3 H-Thymidine indicates S phase entry. We found that progression from G1/ G0 to S phase was not aected by the loss of p53 or the presence of the lck-PARP-DBD transgene ( Figure  4) .
However, the entry of splenic T-cells into S phase after antigenic stimulation was ineective in cells with intact p53 that received a single dose of 2 Gy xirradiation. In this case, almost no cells could be detected to have entered S phase upon antigenic stimulation re¯ecting the activity of p53 to arrest G1/ S progression of damaged cells (Figure 4 ). In contrast, , ®lled circles). Both lck-PARP-DBD transgenic mice and p53 null mice had been backcrossed for at least 10 generations with inbred C57BL/6 animals. Tumor rates were compared within animals from the same breeding experiment. All groups of animals depicted in (a) and (b) were observed over a time period of 220 days for the development of lymphoma and were sacri®ced when moribund. Single lck-PARP-DBD transgenic mice did not develop tumors Figure 3 T-cell lymphoma in lck-PARP-DBD/p53 7/7 mice. Flow cytometric analysis of one tumor that originated in the thymus but manifested only in the peripheral lymphoid organs. Tumor cells are positive for both CD4 and CD8 surface markers. Single cell suspensions were prepared as described (MoÈ roÈ y et al., 1993) at the time of autopsy from thymus in PBS supplemented with 0.5% FCS (staining solution). Cells were washed in this solution and incubated on ice for 30 min with antibodies directly conjugated with¯uorochromes a substantial amount of anti CD3 stimulated, p53 negative splenic T-cells entered S phase after irradiation independently of the presence of the dominant negative form of PARP-1 (Figure 4 ). This indicated that p53 de®cient T-cells have lost a G1/S cell cycle control checkpoint and continue to progress through this checkpoint even with damaged DNA that cannot be eciently repaired when PARP-1 activity is blocked. In the currently favored model, block of apoptosis and loss of a G1/S damage checkpoint in p53 negative cells leads to an accumulation of mutations and eventually to the formation of malignantly transformed cells. Our data demonstrate that this process is markedly accelerated when DNA single strand break repair is blocked and underscore the importance of cell cycle checkpoints in tumor suppression.
Most recently the investigation of the role of PARP-1 and p53 and their potential cooperation in tumor suppression produced con¯icting results. Two independent studies used PARP-1 de®cient mice generated by gene targeting and crossed them with p53 null mice to produce double de®cient animals. Whereas one study found acceleration of tumorigenesis in PARP-1 7/7 / p53 7/7 mice (Tong et al., 2001 ) the other study reported the opposite result and showed that the deletion of both PARP-1 and p53 genes led to an increased tumor latency in mice (Conde et al., 2001) . In addition, a third study which investigated cancer susceptibility of PARP-1 knock out mice to the nitrosamine BHP demonstrated elevated rates of hemangiomas and lung adenomas in PARP-1 knock out mice compared to treated wild-type animals (Tsutsumi et al., 2001) . At present, there is no obvious explanation that would reconcile these ®ndings. It has been demonstrated that PARP-1 has another role in transcriptional control by regulating the activity of NF-kB that has been shown to be independent of DNA binding and poly(ADP-ribose) polymer synthesis : TCR b chain rearranged. The latency period for tumor appearance is given in days (d) Figure 4 Expression of a PARP-1 DBD transgene does not aect the disruption of the G1 cell cycle checkpoint in p53 null mice. Incorporation of radioactively labeled thymidine by splenocytes after antigenic stimulation, before (gray bars) and after x-irradiation (black and white bars). Single cell suspensions of spleens were plated on 96-well plates coated with 10 mg/ml anti-CD3 (145-2C11) and 2 mg/ml anti-CD28 (37.51, both Pharmingen) for 2 h at 378C. 1610 5 splenocytes per well were plated in triplicate in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 50 mM b-mercaptoethanol, 100 IU penicillin, 100 mg/ml streptomycin, and 50 mg/ml gentamicin. Cells were pulsed for 8 h with 3 H-methyl thymidine (Amersham) and were harvested and counted (Betaplate Counter/ Wallac) before and at 6 and 12 h after a single dose of 2 Gy xirradiation (Oliver et al., 1999) . Therefore, an experimental system using PARP-1 knock out cells may be more complex than cells expressing a dominant negative PARP-1 allele as it is the case in the lck-PARP-DBD transgenic mice used here. In our case, solely the PARP-1 DNA binding and thus the poly(ADP-ribose) polymer dependent functions such as DNA repair are blocked, but the endogenous PARP-1 is present and can still ful®ll other tasks, for instance in transcriptional control through NF-kB. Hence, using the PARP-1 dominant negative transgene approach, we were able to separate the dierent functions of PARP-1 and to investigate exclusively whether the DNA repair function of PARP-1 cooperates with apoptosis and cell cycle control in the process of tumor suppression without disturbing the link of PARP-1 to NF-kB.
In addition, PARP-1 knock out cells appear to have restored the G1/S damage checkpoint in p53 negative cells (Conde et al., 2001) . This contrasts with the situation in T-cell from lck-PARP-DBD/p53 7/7 mice described here and represents another dierence of both experimental systems. How the damage induced cell cycle checkpoint is restored by the loss of the PARP-1 protein in the absence of p53 is unclear. Given the importance of cell cycle checkpoint control in tumor suppression it is conceivable that this dierence explains why tumorigenesis is accelerated in lck-PARP-DBD/p53 7/7 mice but not in PARP-1
animals. However, the results reported in the ®rst study (Tong et al., 2001 ) that tumorigenesis is accelerated in double PARP-1 7/7 /p53 7/7 null animals are clearly con¯icting and are not consistent with this view. Another explanation for the discrepancy between these studies with PARP-1 knockout mice might be dierent genetic backgrounds of the animals since it has been demonstrated that strain dependent modi®er genes can alter the onset and type of lymphoma development in p53 7/7 mice (Van Meyel et al., 1998) . Moreover, given that PARP-1 regulates NF-kB activity, which controls a number of pathways responding to infections, it is possible that altered in¯ammatory reactions are responsible for the dierent outcome of both studies. Since our animal model described here, the lck-PARP-DBD transgenic mouse, reduces the experimental system under investigation to one cell type and to isolated functions of PARP-1 we conclude that PARP-1 and p53 cooperate in tumor suppression by maintaining DNA repair, induction of apoptosis and cell cycle arrest as a response to DNA damage.
